Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 31

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 31
---
 1,380 |
| Shareholders' equity      |     | $ |         5,302 |     | $ |             5,137 |

|                                                  |     | Six Months Ended June 30, | 2025 |     |   |   2024 |     |   | Change |
|:-------------------------------------------------|:----|:--------------------------|-----:|:----|:--|-------:|:----|:--|-------:|
| Cash provided by operating activities            |     | $                         |  349 |     | $ |    438 |     | $ |    -89 |
| Cash (used in) investing activities              |     | $                         |  -17 |     | $ | -1,480 |     | $ |  1,463 |
| Cash (used in) financing activities              |     | $                         | -419 |     | $ |   -525 |     | $ |    106 |
| Increase (decrease) in cash and cash equivalents |     | $                         |  -87 |     | $ | -1,567 |     | $ |  1,480 |
| Exchange Rate adjustments                        |     | $                         |    3 |     | $ |    -15 |     | $ |     18 |

Net cash provided by operating activities is primarily related to our operating profit, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. The $89 million decrease in net cash provided by operating activities is primarily driven by a $268 million increase in corporate taxes paid in the first six months of 2025 compared to first six months of 2024. The increase in corporate taxes paid was a result of a higher corporate tax payable as of December 31, 2024 compared to December 31, 2023, resulting from the transfer of ProfoundBio related intangible assets to Genmab A/S. This decrease was partly offset by an increase in operating profit of $196 million.

Net cash used in investing activities primarily reflects differences between the proceeds received from the sale and maturity of our investments and amounts invested, and the cash paid for investments in tangible and intangible assets. The $1,463 million decrease in net cash used in investing activities is primarily driven by the acquisition of ProfoundBio during the second quarter of 2024, partly offset by the sales and maturities of marketable securities exceeding purchases to a greater extent